| No. |
DrugBank |
Drug (Description in trials)
[Number of descriptions] |
KEGG DRUG * | KEGG GENES *
[Number of genes] |
KEGG PATHWAY
[Number of pathways] |
Disease ID *
[Number of diseases] |
| 1 | Avacincaptad pegol | [1] Avacincaptad pegol; | - |
- |
- |
[1] 301 |
| 2 | Cholesterol | [9] 3h-cholesterol bound to albumin; Cholesterol; Cholesterol supplementation; Crystalline cholesterol oil-based suspension; Egg substitute, without cholesterol; Egg yolk preparation with cholesterol; Lysosomal acid lipase, esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa); Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa); Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa); | D00040 |
- |
- |
[7] 19, 90, 160, 259, 261, 301, 310 |
| 3 | Doconexent | - | - |
- |
- |
[7] 6, 49, 90, 94, 240, 299, 301 |
| 4 | Emixustat | [3] Emixustat; Emixustat hydrochloride; Emixustat hydrochloride (acu-4429); | D10348 |
- |
- |
[1] 301 |
| 5 | Fomepizole | - | D00707 |
[3] ADH1A, ADH1B, ADH1C |
[8] Chemical carcinogenesis, Drug metabolism - cytochrome P450, Fatty acid degradation, Glycolysis / Gluconeogenesis, Metabolic pathways, Metabolism of xenobiotics by cytochrome P450, Retinol metabolism, Tyrosine metabolism |
[1] 301 |
| 6 | Interferon gamma-1b | [2] Interferon gamma-1b; Interferon gamma-1b (actimmune); | D00747 |
[2] IFNGR1, IFNGR2 |
[19] Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Salmonella infection, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
[7] 65, 85, 90, 228, 299, 301, 326 |
| 7 | Ranibizumab | [3] Intravitreal injection ranibizumab; Ranibizumab; Ranibizumab injection (0.5 mg); | D05697 |
[1] VEGFA |
[21] AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
[4] 34, 166, 227, 301 |